CRMD News and Press, CorMedix Inc. From 08/13/21

Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q2 2021 Earnings Call Transcript...

CorMedix Inc. (CRMD) Q2 2021 Earnings Conference Call August 12, 2021, 04:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Khoso Baluch - CEO Phoebe Mounts - EVP and General Counsel Matt David - EVP and CFO Conference Call Participants Jason Butler - JMP Securities Joon Lee - Tr...

BERKELEY HEIGHTS, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for t...

BERKELEY HEIGHTS, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its...

NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) in the United States District Court for the District of New Jersey on...

IDMC meets on June 29 for Superiority review. Mino-Lok has no competition. Price target increased to $10. Mino-Lok has Fast Track designation. Enough cash through commercialization. For further details see: Citius: Halt For Superiority On The Horizon

BERKELEY HEIGHTS, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed t...

BERKELEY HEIGHTS, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix managemen...

BERKELEY HEIGHTS, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management...

The market's recently volatility has made some investors step back and think about their holdings. While this bout of volatility may be temporary, it's always good to stick to stocks that have a higher potential for outperformance and avoid stocks that have a higher potential for underperform...